Interlaboratory comparison of size measurements on nanoparticles using nanoparticle tracking analysis (NTA)

Patrick Hole · Katherine Sillence · Claire Hannell · Ciaran Manus Maguire · Matthias Roesslein · Guillaume Suarez · Sonja Capracotta · Zuzana Magdolenova · Limor Horev-Azaria · Agnieszka Dybowska · Laura Cooke · Andrea Haase · Servane Contal · Stein Manø · Antje Vennemann · Jeans-Jacques Sauvain · Kieran Crosbie Staunton · Sergio Anguissola · Andreas Luch · Maria Dusinska · Rafi Korenstein · Arno C. Gutleb · Martin Wiemann · Adriele Prina-Mello · Michael Riediker · Peter Wick

Received: 7 June 2013 / Accepted: 26 October 2013 / Published online: 19 November 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract One of the key challenges in the field of nanoparticle (NP) analysis is in producing reliable and reproducible characterisation data for nanomaterials. This study looks at the reproducibility using a relatively new, but rapidly adopted, technique, Nano-particle Tracking Analysis (NTA) on a range of particle sizes and materials in several different media. It describes the protocol development and presents both the data and analysis of results obtained from 12 laboratories, mostly based in Europe, who are primarily QualityNano members. QualityNano is an EU FP7 funded Research Infrastructure that integrates 28 European analytical and experimental facilities in nanotechnology, medicine and natural sciences with the goal of developing and implementing best practice and quality in all aspects of nanosafety assessment. This study looks at both the development of the protocol and how this leads to highly reproducible results amongst participants. In this study, the parameter being measured is the modal particle size.

Keywords Nanoparticle · Interlaboratory comparison · Reproducibility · Polydispersity · Toxicology · Health and safety implications

Sonja Capracotta, Zuzana Magdolenova, Limor Horev-Azaria, Agnieszka Dybowska, Laura Cooke, Andrea Haase, Servane Contal, Stein Manø, Antje Vennemann, Jeans-Jacques Sauvain, Kieran Crosbie Staunton, Sergio Anguissola, Andreas Luch, Maria Dusinska, Rafi Korenstein, Arno C. Gutleb, Martin Wiemann, Adriele Prina-Mello, Michael Riediker, Peter Wick have contributed equally to this study.

P. Hole · K. Sillence · C. HannellNanoSight Ltd., Minton Park, London Road, Amesbury, Wiltshire SP4 7RT, UK e-mail: patrick.hole@nanosight.com

C. M. Maguire · K. C. Staunton · A. Prina-MelloTrinity Centre for Health Sciences, Department of Clinical Medicine, Institute of Molecular Medicine, St. James’s Hospital, James Street, Dublin 8, Ireland

M. Roesslein · P. WickLaboratory for Materials - Biology Interactions, Swiss Federal Laboratories for Materials Research and Testing (Empa), Lerchenfeldstrasse 5, 9014 St Gallen, Switzerland

G. Suarez · J.-J. Sauvain · M. RiedikerInstitute for Work and Health, Rte. de la Corniche 2, 1066 Epalinges-Lausanne, Switzerland

S. CapracottaNanoSight USA, 1415 Washington Heights, Rm 6611, Ann Arbor, MI 48109, USA

Z. Magdolenova · S. Manø · M. DusinskaHealth Effects Laboratory, Department of Environmental Chemistry, Norwegian Institute for Air Research, Instituttveien 18, P.O. Box 100, NO-2027 Kjeller, Norway
Introduction

Nanotechnology is rapidly developing new applications and advanced materials into many manufacturing areas from information technology, energy storage and harvesting, to radically new medical technologies. The projected market figure for nanotechnology incorporated in manufactured goods by 2020 is approximately 3,000 billion US dollars worldwide (Roco 2011). Such exponential global growth is, however, calling for responsible and quantitative evaluation of the development of manufacturing nanomaterials and its associated metrology. This is particularly true since nanomaterials have unique physical and chemical properties that are useful for various consumer and industrial applications, but these very same properties may give rise to unique biological reactivity. This has led to mounting concerns over the safety of nanomaterials and pressure to control the potential risks (Schrurs and Lison 2012).

To ensure compliance with environmental protection guidelines (OECD 2009) nanoparticles (NPs) produced, either directly or indirectly, must be fully characterised (Hassellöv et al. 2008; Tiede et al. 2009). This is fundamental in all areas of research and industry. Among the different properties which need full characterisation, the size of NPs and the quality and stability of their dispersion often have a profound effect on their interactions with organisms and the environment. It has been extensively reported that NP response to the surrounding environment is size dependent (Jiang et al. 2008; Tenzer et al. 2011) due to their large surface area that interacts with their surrounding matrix, and this can influence their reactivity with toxicity targets in the cells (Lison and Huaux 2011; Tsao et al. 2011). This has been found to be particularly relevant when the NPs are used for targeted applications. For instance, gold NPs have been used in medical application as contrast agents or nanocarriers (Tong et al. 2009; Kim et al. 2010), polystyrene NPs are a good model for diagnostics and environmental applications due to their relatively well-defined size and low cost (De Jong and Borm 2008; Fritz et al. 1997), silica NPs as drug delivery carriers due to their size-dependent toxicity (Greish et al. 2012; Lin and Haynes 2010; Mohamed et al. 2012) and iron oxide nanoparticles (SPIONS) as therapeutics carriers (Prina-Mello et al. 2013). Therefore, when working with NPs, it becomes crucially important to fully characterise the NPs physico-chemical properties and their interaction with the surrounding matrix or environment (Montes-Burgos et al. 2010; Warheit 2008). This is particularly true when investigating the efficacy and biodistribution of NPs in vivo where it is extremely difficult to validate any mechanism of interactions or kinetics from the biodistribution data without having accurate particle size distributions (Gaumet et al. 2008). Therefore the dispersion state of the NPs in solution becomes a main parameter to be investigated which can be correlated to particle stability, and subsequent shelf life and efficacy (Hassellöv et al. 2008). Thus, the implications are not only limited to biological applications but also to environmental and ecological perspectives, as well as regulatory (Elsaesser and Howard 2012; Hanna et al. 2013).
In fact, it has been extensively reported by many studies that the nature of the media in which the NPs are dispersed is driving their response and interaction at a biological level (Lison and Huaux 2011; Schrurs and Lison 2012). Several reports have defined and characterised some aspects of this bio–nano interaction through association with the NP physiochemical properties (Nel et al. 2009); particle size being the starting aspect for aggregation consideration, formation of protein coronas (Casals et al. 2010; Cedervall et al. 2007) and subsequent shielding of targeting moieties resulting in loss of NP specificity (Salvati et al. 2013).

Several techniques have been developed for measuring particle size, shape and dispersity from a suspension of particles; electron microscopy (EM), dynamic light scattering (DLS), disc centrifugation, Coulter principle and NTA amongst others. Some of these are labour intensive and time demanding whereas others are cost effective and user friendly. The most frequently used and user friendly NP size characterisation technique is DLS (Filipe et al. 2010). This technique measures the fluctuations in scattered light intensity caused by NPs moving under Brownian motion (Frisken 2001). However, the analysis is weighed towards larger particle size, and as a result, the presence of NP aggregates will bias the particle size distribution, resulting in inaccurate size determination. The use of NTA, with a lower concentration detection limit compared to DLS, analysing NPs on a particle by particle basis, offers a new method for the visualisation and characterisation of NPs in suspension.

The QualityNano project is a European Union Framework Programme 7 funded infrastructure project for developing best practice and innovation in nanomaterial safety testing. One fundamental activity of the QualityNano project is the establishment of quality control and quality assurance conditions for nanomaterial safety and assessment. As technologies and methodologies develop in this area, and the number of end-users increases, the validity of the methodologies and standards needs to be continuously monitored and updated to the most stringent industrial requirements. Quality standards can only be achieved by enlarging statistical numbering and introducing multivariate analysis. This can be achieved by adopting a systematic approach to parametrically assess the interlaboratory, inter-batches and multi-users variation. NTA has only been commercialised since 2006 (Filipe et al. 2010) but the technique has, in recent years, grown rapidly in its adoption and use, with over 600 systems and 800 third party papers, consolidating the technique across many areas of application, such as therapeutic NP characterisation, developing solutions for diagnostics (e.g., exosomes), drug delivery and cancer treatment, development of bioanalytical assays, vaccine characterisation and nanotoxicology. Therefore the adoption of an interlaboratory comparison (ILC) to validate the NTA technique, by assessment of panels of nanomaterials from within the QualityNano project, derives from the extensive knowledge accumulated and shared between the QualityNano partners and NanoSight Ltd., Amesbury, UK, the company that manufactures the NTA systems. NTA performance is therefore assessed by a structured ILC using defined samples measured by multiple laboratories in order to ascertain the competence of the laboratory, the quality of the standard operating procedures (SOPs) and the reproducibility of the technique. Furthermore, through the use of defined protocols for measurement of standardised samples, the ability of the different NTA systems under evaluation to produce reliable and reproducible results can be investigated (multi-user’s variation). It is therefore important to highlight that the uncertainty in the validity and consistency of results could have important implications for the determination of the effects of NPs since different results could be generated when applying different starting dispersions, thus confusing the outcomes. During NP characterisation, using best practice in-house developed SOPs does not always guarantee consistency with other laboratories, as previously shown in Roebben’s study for the DLS technique (Roebben et al. 2011). The recommendation for adopting an ILC study is therefore ideal for both developing and testing protocols, as demonstrated in the study presented here, which has been strongly supported within the QualityNano consortium by NanoSight. The authors in this manuscript adopted the ILC principles for assessment from Roebben and coworkers and transferred this to the NTA technique. For instance, this study adopted the use of National Institute of Standards and Technology (NIST) traceable NPs and the supply and modification of protocols following each analysis round. Reproducibility analysis was carried out using classical statistical analysis based around the arithmetic mean values using the ISO 5725-2 approach (ISO 1994) and robust statistical analysis centred around methods described in ISO 5725-5 (ISO 1998). The ILC was also assessed in
its inter-batch and multi-users variation carried out over four rounds using blind samples and well-defined SOPs to produce a protocol for NP size characterisation using NTA in order to reinforce the robustness of the NTA technique, its standardisation and effort towards defining regulatory guidelines.

NTA: technique principle and details

NTA utilises the properties of both light scattering and Brownian motion in order to obtain particle size distributions of samples in liquid suspension. A laser beam (of arbitrary wavelength but typically those available from laser diodes operating at 635, 532, 488, or 405 nm) is passed through a prism-edged glass flat within the sample chamber. The angle of incidence and refractive index of the glass flat are designed to be such that when the laser reaches the interface between the glass and the liquid sample layer above it the beam refracts, resulting in a compressed beam with a reduced profile and high power density. The particles in suspension in the path of this beam scatter light in such a manner that they can be easily visualised via a long working distance, 20× magnification microscope objective, fitted to an otherwise conventional optical microscope. Onto this is mounted either a charged coupled device (CCD), electron multiplied charged coupled device (EMCCD) or high-sensitivity complementary metal–oxide–semiconductor (CMOS) camera, operating at approximately 30 frames per second (fps), which captures a video file of the light scattered by particles moving under Brownian motion, within a field of view of approximately 100 μm × 80 μm × 10 μm (Fig. 1).

Within the field of view, particles are seen moving under Brownian motion, either directly by eye using the microscope oculars or via the camera. The proprietary NTA software records a video file (of typically 30–60 s duration) of the particles viewed and then simultaneously identifies and tracks the centre of each particle on a frame-by-frame basis. The image analysis software then determines the average distance moved by each particle in the x and y directions. This value allows the particle diffusion coefficient (\(D_t\)) to be determined, from which, if the sample temperature (\(T\)) and solvent viscosity (\(\eta\)) are known, then the sphere-equivalent hydrodynamic diameter (\(d\)) of the particles can be identified using the Stokes–Einstein equation (Eq. 1).

\[
D_t = \frac{TK_B}{3\pi\eta d}
\]  

where \(K_B\) is Boltzmann’s Constant.

Brownian motion occurs in three dimensions but NTA observes motion only in two dimensions. However, the fact that three-dimensional Brownian motion is tracked only in two dimensions is accounted for by the use of the following variation of the Stokes–Einstein equation (Eq. 2). It is possible, however, to determine \(D_t\) from measuring the mean squared displacement of a particle in one, two or three dimensions (Eq. 2, respectively).

\[
\langle x^2 \rangle = \frac{2TK_B t}{3\Pi\eta d} \quad \langle (x,y)^2 \rangle = \frac{4TK_B t}{3\Pi\eta d} \\
\langle (x,y,z)^2 \rangle = \frac{2TK_B t}{\Pi\eta d}
\]  

Thus, in the case where measurement of movement in two dimensions is made; Eq. 2b is employed.

One crucial advantage that NTA has over other measurement techniques is that it is not biased towards larger particles or aggregates. The software is based on the tracking of single particles, whereas typical DLS techniques place a strong bias on the largest particles present in the sample (Filipe et al. 2010). NTA therefore allows for the detection of secondary peaks, which may not be detectable or resolvable using other traditional measurements.

NTA: standardisation

Early steps towards standardisation of NTA have recently been demonstrated by an ASTM guidance
paper published about the technique (ASTM 2012) providing an overview of the methodology to be followed for good practice and discussing aspects such as principles and limitations of the method, considerations of sampling, necessary concentration and interpretation of results, with particular reference to comparison with other techniques. An International Standardisation Community at ISO TC24 welcomed the submission of a new work item proposal on Particle Tracking Analysis (PTA)/NTA at their recent meeting (ISO 2013).

Standardisation of the NTA technique has previously been difficult to achieve due to the number of software options that a user has been required to choose in order to make a measurement. This was highlighted in an excellent paper comparing DLS and NTA (Filipe et al. 2010) which highlighted this issue of subjectivity of NTA results with user settings. Table 1 summarises the development of the software since that point, showing the progression of algorithm development allowing these settings to be effectively automated.

The ILC assessment design in this study employs the NTA2.3 software version which had three settings that users should set. These were: (1) capture time (unified for all laboratories and users by supplied SOP), (2) camera level and (3) detection threshold (guidance provided for 2 and 3 by the supplied SOP).

### NTA: regulatory aspect

It is expected that the outcomes of ILC studies of the NTA technique could contribute to the defining of regulatory policy and guidelines for the adoption of safe nanotechnology procedures in line with the goals of QualityNano, through the generation of SOPs for the accurate and reproducible size characterisation of NPs dispersed in water-based solvents.

### Materials and methods

#### Test materials

NIST traceable polystyrene nanospheres, nominally 100 and 200 nm (1 % solids), were purchased from Thermo Fisher Scientific Inc., whilst gold NPs, nominally 60 and 80 nm (0.01 % solids), were purchased from BB International, Cardiff. Ham’s F10 nutrient mix and Bovine Serum Albumin (BSA) were purchased from Sigma Aldrich Co. HPLC grade water was purchased from Rathburn Chemicals Ltd., Scotland. 0.02 μm Anotop 25 syringe filters (Whatman GmbH, Germany) were used to filter water and BSA samples prior to analysis.

#### Samples preparation

Samples were aliquoted from a single lot prior to the start of each round (either pre-diluted or neat), ensuring all participating labs received aliquots of the same materials. Rounds 1 and 2 were carried out on the same four monodisperse samples, dispersed in water, round 3 analysed three monodisperse samples, again dispersed in water. Round 4 included a bimodal

---

### Table 1 History of development of NTA software showing list of parameters along with the number of user adjustable settings for each parameter

| Part of analysis | Year | NTA Version | 2009 | 2010 | 2011 | 2012 |
|------------------|------|-------------|------|------|------|------|
| Data collection  |      |             |      |      |      |      |
| Capture time     |      | 2.0         | 215  | 215  | 5    | 5    |
| Shutter          |      | 2.1         | 1500 | 1500 | 1    | 1    |
| Camera gain      |      | 2.2         | 680  | 680  | 16   | 16   |
| Gamma            |      | 2.3         | 2    | 1    | 1    | 1    |
| Data analysis    |      |             |      |      |      |      |
| Brightness       |      |             | 186  | 186  | 1    | 1    |
| Image gain       |      |             | 1000 | 1000 | 1    | 1    |
| Blur             |      |             | 5    | 4    | 1    | 1    |
| Detection threshold |    |             | 188  | 100  | 50   | 20   |
| Max blob size    |      |             | 3000 | 1    | 1    | 1    |
| Min track length |      |             | 183  | 1    | 1    | 1    |
| Min expected particle size | |             | 9    | 9    | 4    | 1    |
| # Free user setting |    |             | 11   | 8    | 4    | 3    |
| # Variations     |      |             | \(3.8 \times 10^3\) | \(1.5 \times 10^7\) | \(1.6 \times 10^4\) | \(1.6 \times 10^3\) |
sample, and monodisperse nanospheres dispersed in biological media with and without the addition of BSA. The details of the composition and characteristics of the samples used in the present study are summarised in Table 2.

All samples were distributed from NanoSight. Samples for rounds 1 and 2 were prepared by University College Dublin, samples for rounds 3 and 4 were prepared by NanoSight. Protocols were all developed and distributed by NanoSight. Effort was taken to ensure samples were always analysed blind by participants, however, the solvent and the material were known, for MSDSs to be distributed.

Participants and systems

Twelve Laboratories from Europe and the USA participated in the four rounds of the ILC using instruments from NanoSight Ltd., Amesbury, UK, between September 2012 and April 2013 as per manuscript authorship. Laboratories were each allocated a unique participant number allowing results to remain anonymous. The participants in this comparison were not pre-screened in any way, some users having received no direct training on the system in their laboratory. The key characteristics of the group were that they were eager to ensure that they were using their systems correctly and to acquire reproducible results. Participants were given no additional training, although where issues/outlying results were identified, they were investigated thoroughly to establish the root cause, the participants informed and the protocol appropriately improved (where possible).

Details of the NanoSight platforms, laser wavelengths and camera type used by each laboratory are given in Table 3. Laboratories reported results in the form of summary files (output by NTA) for each sample. Results were collated and analysed by NanoSight.

Protocol Development

Results were disseminated to all partners following rounds 2, 3 and 4. This allowed discussion with partners about how to proceed and allowed the group’s

| Table 2 | Characteristics of nanoparticle samples used in the study |
|---|---|---|---|---|
| Gold | BBI | 1 and 2 | 30 ± 2 (TEM) | ~0.01 | H₂O |
| Carboxylated polystyrene | Invitrogen | 1 and 2 | 100 ± 11 (TEM) | ~0.1 | H₂O |
| Aminated polystyrene | Polysciences | 1 and 2 | 100 | ~0.1 | H₂O |
| Silica | Polysciences | 1 and 2 | 100 | ~0.1 | H₂O |
| Polystyrene | Thermo Scientific | 3 | 102 ± 3 (TEM) | ~1 | H₂O |
| Gold | BBI | 3 | 60 ± 3 (TEM) | ~0.01 | H₂O |
| Gold | BBI | 3 | 81 ± 4 (TEM) | ~0.01 | H₂O |
| Polystyrene | Thermo Scientific | 4 | 102 ± 3 (TEM) | ~1 | H₂O, Ham’s F10 Nutrient Mix, BSA |
| Polystyrene | Thermo Scientific | 4 | 203 ± 5 (TEM) | ~1 | H₂O |
| Gold | BBI | 4 | 81 ± 4 (TEM) | ~0.01 | H₂O |

| Table 3 | NanoSight systems used for ILC by participant number |
|---|---|---|---|---|
| Lab code | Platform | Camera | Laser wavelength (nm) | Temperature control |
| 1 | LM10 | sCMOS | 532 | Yes |
| 2 | NS500 | EMCCD | 532 | Yes |
| 3 | NS500 | sCMOS | 405 | Yes |
| 4 | NS500 | sCMOS | 405 | Yes |
| 5 | LM20 | CCD | 635 | No |
| 6 | LM10 | CCD | 635 | No |
| 7 | LM10 | CCD | 635 | No |
| 8 | LM20 | CCD | 635 | No |
| 9 | NS500 | sCMOS | 405 | Yes |
| 10 | LM20 | CCD | 635 | No |
| 11 | LM10 | EMCCD | 405 | Yes |
| 12 | LM10 | sCMOS | 405 | No |
expertise to be employed. Choice of samples for a round was only made following the collection and analysis of the results from the preceding round. This allowed an assessment of the progress, the choice of appropriate samples to challenge progress and time for development/improvement of the protocol.

**ILC round 1**

A preliminary ILC (round 1) was performed on 4 samples (nominally gold 30 nm, 100 nm carboxylated polystyrene, 100 nm aminated polystyrene and 100 nm silica), without any protocol provided. Participants analysed the samples according to their own ‘in-house’ protocols for using NTA. This highlighted a number of issues, such as the need to perform replicate measurements on each sample and a need to ensure sample dilution to an appropriate concentration for the NTA system, which were incorporated into the protocol for subsequent rounds.

**ILC round 2**

Round 2 analysed the same samples as round 1, but under a protocol developed to standardise methods between participating laboratories. The protocol covered sample handling and storage, sample preparation (standard dilutions for each sample), video capture (60 s duration) and data analysis and export. Each laboratory analysed each sample in triplicate to allow statistical analysis under repeatability conditions.

**ILC round 3**

The results and particle sizes from rounds 1 and 2 being known by the participants, three new samples were supplied for analysis in round 3 (nominally 100 nm polystyrene, 60 nm gold and 80 nm gold), along with an updated protocol, which was amended in light of the results for round 2. Samples were shipped with a temperature sensor which indicated if the contents were exposed to temperatures below 4 °C or above 29 °C.

**ILC round 4**

Unlike previous rounds, where all the samples were monodisperse nanospheres diluted in water, round 4 investigated both a bimodal sample (80 nm gold and 200 nm polystyrene) and monodisperse nanospheres (100 nm polystyrene) suspended in biological media (Ham’s F10 nutrient mix) and biological media supplemented with BSA (Ham’s F10 nutrient mix plus 5 mg/ml BSA). This allowed analysis of samples in more complex aqueous solutions than water. Samples were shipped with two temperature sensors, to indicate if the contents were exposed to temperatures below 4 °C or above 29 °C.

**Results and discussion**

Laboratories submitted reports containing modal sizes for each replicate of each sample run, along with the particle size distributions, with outlying results being discarded [consisting of 0 (of 48), 6 (of 48), 0 (of 36) and 3 (of 44) from rounds 1, 2, 3 and 4, respectively]. During each of the rounds where technical causes could be unambiguously identified or it was ascertained that a participant was not fully complying with the protocol, these results were discarded. This was (usually) assumed to be a weakness of the protocol, which was then modified to better ensure compliance in future ILC rounds.

Method reproducibility analysis was carried out using methods laid out in ISO 5725-2 (ISO 1994). The modal sizes obtained for each sample from rounds 2, 3 and 4 were analysed using both classical [average and standard deviation (SD) based] and robust [median and median absolute deviation based (MAD)] statistics as per ISO 5725-5 (ISO 1998). Robust statistics has the advantage that it is much less sensitive to outliers and so a median value better represents the centre of a distribution of results reported from different laboratories. In addition, the SD describing a second order effect is considerable more sensitive towards results that are further away from the mean value, and are therefore potential outliers, than towards all the results that are close to the mean value. MAD, as median absolute deviation, is less sensitive to large deviations at the extremes.
Analysis of the results obtained from ILC round 1 shows the variation and lack of reproducibility of results from the 12 laboratories when no protocol was supplied. Figure 2 summarises the modal size results obtained during ILC round 1 on 30 nm gold nanoparticles based on standard (a) and robust (b) statistical analysis. It appears clear from Fig. 2 that results from 2 of 12 laboratories do not match with the data of the other 10 partners. Therefore, in the case of classic statistical analysis the mean value (solid line), median (dashed line) and 95 % confidence intervals (dotted line) are also shown.

![Graph A](image1.png)
![Graph B](image2.png)

**Fig. 2** Modal particle size for 30 nm gold particles from ILC round 1 showing results from each partner ordered by increasing modal value based on a classical (±2 SD) and b robust (±2 MAD) statistical analysis. The mean value (solid line), median (dashed line) and 95 % confidence intervals (dotted line) are also shown.

The coefficient of variation of 54.8 %, can easily be attributed to the absence of guidance in the ILC round 1 which included users who had had no training (either internal or external) in the technique or on their system. The lack of an adequately defined measurand in ILC round 1 resulted in an excessive uncertainty of the measurement, as predicted by the guide to the uncertainty in measurement (GUM) (JCGM 2008).

Between the last 3 rounds, the protocols were upgraded on the basis of issues encountered in the preceding round, covering all the aspects of the experimental process: sample shipping (temperature sensors), sample handling and preparation (e.g., dilution), sample storage, control of measurement parameters (e.g., video control, detection threshold), software update (e.g., vibration check) and analytical data treatment (e.g., number of replicates, statistic models).

The positive impacts that a well-established protocol and good compliance exert on the robustness of the NP size determination with NTA technique is further emphasised when we consider the calculated coefficient of variation as a comparative parameter between the different ILC rounds. The percentage coefficients of variation are summarised in Table 4 showing a

| ILC Round                | 1 (% CV) | 2 (% CV) | 3 (% CV) | 4 (% CV) |
|--------------------------|----------|----------|----------|----------|
| 30 nm gold               | 54.8     | 10.5     |          |          |
| 100 nm carboxylate       | 33.3     | 9.3      |          |          |
| polystyrene              |          |          |          |          |
| 100 nm aminated polystyrene | 31.2   | 15.9     |          |          |
| 100 nm silica            | 34.5     | 10.0     |          |          |
| 100 nm polystyrene       | 3.5      | 3.1      |          |          |
| 60 nm gold               | 5.1      |          |          |          |
| 80 nm gold               | 4.1      |          |          |          |
| 100 nm                   |          |          |          |          |
| polystyrene + nutrient Mix | 3.7     |          |          |          |
| 100 nm                   |          |          |          |          |
| polystyrene + nutrient mix + BSA | 4.7    |          |          |          |
| 80 nm gold (in bimodal sample) | 5.5   |          |          |          |
| 200 nm polystyrene (in bimodal sample) | 5.2 |          |          |          |
| Average (% CV)           | 38.5     | 11.4     | 4.2      | 4.4      |

* Considering only monodisperse samples
clear link between the improving reproducibility of measurements and successive rounds. The averaged percentage coefficient of variation calculated for monodisperse samples progressively decreases from ILC round 1 to round 4: 38.5, 11.4, 4.2 and 3.8 % (Fig. 3).

Once again, the combination of a powerful analytical technique with improved protocols gave rise to robust and reproducible determination of the modal size of both monodisperse and bimodal nanosphere samples prepared in water and complex biological matrices.

Standard and robust analyses were established with participant results from all ILC rounds. In the case of ILC round 4, the modal size results obtained on a nominal 100 nm polystyrene nanospheres based on classical and robust statistics are reported in Fig. 4a and b, respectively. In that round, the results obtained for 10 laboratories out of a total of 11 are within the 95 % confidence interval and so match with the mean and median values, for both classical and robust statistical analyses. The range of the 95 % confidence interval is dramatically decreased in comparison to the one obtained in ILC round 1. As mentioned earlier, the very low coefficient of variation calculated at ILC round 4 for monodisperse solution of polystyrene nanosphere (3.1 %) strongly emphasises the effect of a well-established SOP for highly reproducible and accurate NTA measurements.

By ILC round 4, the averaged modal particle size distribution resulting from the analysis of 11 laboratories (one laboratory failed to supply data) on monodisperse polystyrene nanospheres (100 nm) diluted in water clearly demonstrates the analytical reliability and power of the NTA technique, when supported by a well-defined SOP, as shown in Fig. 5. The average modal size and coefficient of variation corresponding to this set of measurements were calculated to be 101.7 nm and 3.12 %, respectively. Similarly, during the same round bimodal samples containing a mixture of nominally 80 nm gold (77–85 nm, TEM) and 200 nm polystyrene (203 ± 5 nm, TEM) nanospheres were also analysed and the modal particle size distributions obtained by 11 laboratories are depicted in Fig. 6. In that case, the calculated average modal sizes were
results to be obtained (ILC2), however, the ILC exercise clearly outlines that even a well-defined protocol (much more complete and detailed than what is usually described in the experimental section of published work) can still lead to a (~4 % CV) variability of outcomes. This has clear implications for the on-going debate on the definition of guidelines for reporting research in this field.

The ILC has shown that, with the guidance of a well-written protocol, users of NTA (even those with little or no training on the instrument) are able to obtain reproducible and accurate modal particle size results on a range of samples, both monodisperse and bimodal, on samples dispersed in water or biological media and on particles of different sizes and material composition. It is important to note here that the samples used in this study were all nominally spherical.

This study has shown that a well-designed and focused series of round robins can help identify relevant issues that have a significant effect on measurement results. It has been demonstrated to be an effective way of improving the understanding of the basics of measurement techniques such as NTA. This leads to a better specification of the measurand, and therefore to a more elaborate and more useful protocol, detailing important steps in the measurement procedure.

Future work will include additional rounds involving more complex mixtures and matrices and extension to other measurands that will help improve understanding of the effect of additional parameters that are relevant for these advanced measurement scenarios. With this, the current performance characteristics of NTA can be further determined. This may initiate new developments that remove the current limiting factors. All this would not have been possible without a soundly designed series of round robins. It is envisaged that the challenges to be faced to achieve similar outcomes for biological testing of NP–cell interactions could be even greater, because of the complexity of living organisms and difficulty in controlling such experiments to this level.

Further steps could also be the direct comparison of NTA measurements with other sizing techniques such as measurements based on DLS, which is known to have certain limitations, but is a more established technique.

**Conclusion and outlook**

Overall, it is clear that in the absence of shared guidelines on how to use a system and prepare samples, variability across laboratories can be large even for relatively monodispersed samples (ILC1). The definition of a shared protocol allowed improved
Acknowledgments TCD would like to thank the partial funding support from CAN project (European Regional Development Fund through the Ireland Wales Programme 2007–2013), INTERREG 4A; NAMDIATURE project (FP7 LSP ref 246479) and MULTIFUN project (FP7 LSP ref 262493). TCD would also like to thank Yuri Volkov for technical support and critical discussion provided during the Quality Nano RR. Empa would like to thank the European Union Seventh Framework Programme (FP7/2007–2013) for the funding under Grant Agreement No. 263215 (Marina) and the Competence Centre for Materials Science and Technology Foundation (CCMX) of the Swiss Government (VIGO-Grant Agreement No. 350601). The contribution of the Centre de Recherche Public—Gabriel Lippmann (AG) was in part made possible within NanEAU II (FNR/10/SR/825684—Fonds National de la Recherche Luxembourg). BIR would like to thank Nils Dommershausen for excellent technical support. All authors would like to thank the European Union for QNano (QualityNano)—A pan-European infrastructure for quality in nanomaterials safety testing, FP7-INFRASTRUCTURES-2010-1 (Grant Agreement No. 262163).

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

ASTM (2012) ASTM E2834-12 Standard guide for measurement of particle size distribution of nanomaterials in suspension by nanoparticle tracking analysis (NTA). ASTM International, West Conshohocken. doi:10.1520/E2834-12

Casals E, Pfaller T, Duschl A, Oostingh G, Puntes V (2010) Time evolution of the nanoparticle protein corona. ACS Nano 4(7):3623–3632. doi:10.1021/nm901372t

Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, Dawson K, Linse S (2007) Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 104(7):2050–2055. doi:10.1073/pnas.0608582104

De Jong W, Borm P (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 3(2):133–149

Elsässer A, Howard CV (2012) Toxicology of nanoparticles. Adv Drug Deliv Rev 64(2):129–137. doi:10.1016/j.addr.2011.09.001

Filipe V, Hawe A, Jiskoot W (2010) Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796–810. doi:10.1007/s11095-010-0073-2

Frisken B (2001) Revisiting the method of cumulants for the distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

ASTM (2012) ASTM E2834-12 Standard guide for measurement of particle size distribution of nanomaterials in suspension by nanoparticle tracking analysis (NTA). ASTM International, West Conshohocken. doi:10.1520/E2834-12

Casals E, Pfaller T, Duschl A, Oostingh G, Puntes V (2010) Time evolution of the nanoparticle protein corona. ACS Nano 4(7):3623–3632. doi:10.1021/nm901372t

Cedervall T, Lynch I, Lindman S, Berggård T, Thulin E, Nilsson H, Dawson K, Linse S (2007) Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc Natl Acad Sci USA 104(7):2050–2055. doi:10.1073/pnas.0608582104

De Jong W, Borm P (2008) Drug delivery and nanoparticles: applications and hazards. Int J Nanomed 3(2):133–149

Elsässer A, Howard CV (2012) Toxicology of nanoparticles. Adv Drug Deliv Rev 64(2):129–137. doi:10.1016/j.addr.2011.09.001

Filipe V, Hawe A, Jiskoot W (2010) Critical evaluation of nanoparticle tracking analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27(5):796–810. doi:10.1007/s11095-010-0073-2

Frisken B (2001) Revisiting the method of cumulants for the analysis of dynamic light-scattering data. Appl Opt 40(24):4087–4091

Fritz H, Maier M, Bayer E (1997) Cationic polystyrene nanoparticles: preparation and characterization of a model drug carrier system for antisense oligonucleotides. J Colloid Interface Sci 195(2):272–288. doi:10.1006/jcis.1997.5172

Gaumet M, Vargas A, Gurny R, Delie F (2008) Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69(1):1–9. doi:10.1016/j.ejpb.2007.08.001

Greish K, Thiagarajan G, Herd H, Price R, Bauer H, Hubbard D, Buckle A, Sadekar S, Yu T, Anwar A, Ray A, Ghandehari H (2012) Size and surface charge significantly influence the toxicity of silica and dendritic nanoparticles. Nanotoxicology 6(7):713–723. doi:10.3109/17435390.2011.604442

Hanna S, Miller R, Muller E, Nisbet R, Lenhan H (2013) Impact of engineered zinc oxide nanoparticles on the individual performance of Mytilus galloprovincialis. PLoS One 8(4). doi:10.1371/journal.pone.0061800

Hassellöv M, Readman J, Ranjive J, Tiede K (2008) Nanoparticle analysis and characterization methodologies in environmental risk assessment of engineered nanoparticles. Ecotoxicology 17(5):344–361. doi:10.1007/s10646-008-0225-x

ISO (1994) ISO 5725-2: 1994: Accuracy (trueness and precision) of measurement methods and results. Part 2. Methods for the determination of repeatability and reproducibility. International Organization for Standardization

ISO (1998) ISO 5725-5: 1998, Accuracy (trueness and precision) of measurement methods and results. Part 5. Alternative methods for the determination of the precision of a standard measurement method. International Organization for Standardization, Geneva

ISO (2013) Resolution 254 of the ISO TC24 Plenary meeting, April 2013, Germany

JGCM 100 (2008) Evaluation of measurement data: guide to the expression of uncertainty in measurement. http://www.bipm.org/utils/common/documents/jcgm/JCGM_100_2008_E.pdf

Jiang W, Kim B, Rutka J, Chan W (2008) Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 3(3):145–150. doi:10.1038/nnano.2008.30

Kim D, Jeong YY, Jon S (2010) A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer. ACS Nano 4(7):3689–3696. doi:10.1021/nn901877h

Lin Y-S, Haynes C (2010) Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. J Am Chem Soc 132(13):4834–4842. doi:10.1021/ja910846q

Lison D, Huaux F (2011) In vitro studies: ups and downs of cellular uptake. Nanotechnology 22(6):32–33

Mohamed BM, Verma NK, Davies AM, McGowan A, Crosbie-Staunton K, Prina-Mello A, Kelleher D, Botting CH, Causey CP, Thompson PR, Prijnu GM, Kisin ER, Tkach AV, Shvedova AA, Volkov Y (2012) Ctitullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo. Nanomedicine 7(8):1181–1195. doi:10.2217/nnm.12

Montes-Burgos I, Warczak D, Hole P, Smith J, Lynch I, Dawson K (2010) Characterisation of nanoparticle size and state prior to nanotoxicological studies. J Nanopart Res 12(1):47–53. doi:10.1007/s11051-009-9774-z

Nel AE, Madler L, Veleog D, Xia T, Hoek EMV, Somasundaran P, Klaessig F, Castranova V, Thompson M (2009) Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8(7):543–557

OECD (2009) Guidance manual for the testing of manufactured nanomaterials: OECD sponsorship programme: first revision.
OECD environment, health and safety publications series on the safety of manufactured nanomaterials, 25th edn. Paris
Prina-Mello A, Crosbie-Staunton K, Salas G, del Puerto Morales M, Volkov Y (2013) Multiparametric toxicity evaluation of SPIONs by high content screening technique: identification of biocompatible multifunctional nanoparticles for nano-medicine. Magnetics, IEEE Transactions on 49(1):377–382. doi:10.1109/tmag.2012.2225024
Roco MC (2011) The long view of nanotechnology development: the National Nanotechnology Initiative at 10 years. J Nanopart Res 13(2):427–445. doi:10.1007/s11051-010-0192-z
Roebben G, Ramirez-Garcia S, Hackley VA, Roesslein M, Klaessig F, Kestens V, Lynch I, Garner CM, Rawle A, Elder A, Colvin VL, Kreiling W, Krug HF, Lewicka ZA, McNeil S, Nel A, Patri A, Wick P, Wiesner M, Xia T, Oberdörster G, Dawson KA (2011) Interlaboratory comparison of size and surface charge measurements on nanoparticles prior to biological impact assessment. J Nanopart Res 13(7):2675–2687. doi:10.1007/s11051-011-0423-y
Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, Kelly PM, Aberg C, Mahon E, Dawson KA (2013) Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 8(2):137–143. doi:10.1038/nnano.2012.237
Schrurs F, Lison D (2012) Focusing the research efforts. Nat Nanotechnol 7(9):546–548. doi:10.1038/nnano.2012.148
Tenzer S, Docter D, Rosfa S, Wlodarski A, Kuharev J, Rekik A, Knaier SK, Bantz C, Nawroth T, Bier C, Siritrattananan J, Mann W, Treuel L, Zellner R, Maskos M, Schild H, Stauber RH (2011) Nanoparticle size is a critical physico-chemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. ACS Nano 5(9):7155–7167. doi:10.1021/nn201950e
Tiede K, Hassellöv M, Breitharth E, Chaudhry Q, Boxall ABA (2009) Considerations for environmental fate and ecotoxicity testing to support environmental risk assessments for engineered nanoparticles. J Chromatogr A 1216(3):503–509. doi:10.1016/j.chroma.2008.09.008
Tong L, Wei Q, Wei A, Cheng J-X (2009) Gold nanorods as contrast agents for biological imaging: optical properties, surface conjugation and photothermal effects. Photochem Photobiol 85(1):21–32. doi:10.1111/j.1751-1097.2008.00507.x
Tsao TM, Chen YM, Wang MK (2011) Origin, separation and identification of environmental nanoparticles: a review. J Environ Monit 13(5):1156–1163. doi:10.1039/c1em10013k
Warheit DB (2008) How meaningful are the results of nanotoxicity studies in the absence of adequate material characterization? Toxicol Sci 101(2):183–185. doi:10.1093/toxsci/kfm279